[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good results in 2021

Basel, 3 February 2022Group sales increase 9%1 at constant exchange rates (CER); 8% in Swiss francsPharmaceuticals Divisionsales increase 3%; continued strong demand for newly launched medicines more than offsets impact of biosimilarsDiagnostics Divisionsales grow 29%; strong momentum in base business and continued high demand for COVID-19 testsMajor approvals for medicinessince the last quarter:United States: Susvimo and Vabysmo (age-related blindness)Europe: Gavreto (specific type of advanced lung cancer); Actemra/RoActemra (severe COVID-19); Ronapreve (non-hospitalised COVID-19 patients and prophylaxis)Major approvals for diagnosticssince the last quarter:cobas 5800 (molecular laboratory system); Avenio Edge (sequencing sample preparation system); cobas pulse and cobas infinity edge (digital ecosystem for clinical decision support); additional SARS-CoV-2 testsPromising pipeline: 16 phase III trials initiated, 14 new compounds in phase III trials or filed for approvalRepurchase of Roche sharesfrom Novartis completedCore earnings per share (EPS) grow 6% (+3% in CHF)IFRSnet income totals CHF 14.9 billion (+2%; -1% in CHF)Board proposesdividend increase to CHF 9.30. If approved by shareholders, this would be the 35th consecutive dividend increaseOutlook for 2022: Sales are expected to be stable or grow in the low-single digits (at constant exchange rates). Core earnings per share are targeted to grow in the low- to mid-single digit range (at constant exchange rates), including...

Source: Roche Media News - February 3, 2022 Category: Pharmaceuticals Source Type: news